<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04764864</url>
  </required_header>
  <id_info>
    <org_study_id>PELVITRAU</org_study_id>
    <nct_id>NCT04764864</nct_id>
  </id_info>
  <brief_title>Pelvic Fractures in Polytraumatized Patients With Hemodynamic Instability: Angioembolization vs Preperitoneal Packing</brief_title>
  <official_title>Randomized Multicenter Study on the Management of Pelvic Fractures in Polytraumatized Patients With Hemodynamic Instability: Angioembolization vs Preperitoneal Packing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nuria Llorach-Perucho</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pelvic fracture is a usual injury in trauma patients. An unstable trauma patient with a&#xD;
      pelvic fracture has an elevated risk of death due to pelvic bleeding and the associated&#xD;
      injuries. Traditionally, it has been estimated that the main source of bleeding is venous&#xD;
      and, consequently, the main treatment has been the preperitoneal pelvic packing.&#xD;
      Nevertheless, according to new data, arterial bleeding appears to be a more important source&#xD;
      of pelvic bleeding than it was thought and angioembolization seems to be a good alternative&#xD;
      in the treatment of these injuries. Consequently, it is important to define better the&#xD;
      management of these patients.&#xD;
&#xD;
      This investigation project consists in a clinical trial study, performed by a&#xD;
      multidisciplinary team of many hospitals around the country, in which angioembolization and&#xD;
      preperitoneal pelvic packing are compared. Unstable trauma patients with a pelvic fracture&#xD;
      and no other injuries (negative FAST / peritoneal aspiration, no evidence of bone fractures&#xD;
      or thoracic injuries) will be submitted, in less than 60 minutes from hospital arrival, to&#xD;
      angioembolization or preperitoneal pelvic packing, according to randomization. There will be&#xD;
      a specific timing evaluation of different markers: hemodynamic (vital signs at arrival,&#xD;
      immediately and 24 hours after treatment) and analytic (at arrival and upon entering to the&#xD;
      Intensive Care Unit). Registered variables include: blood cell transfusions, vasoactive drug&#xD;
      requirements, time elapsed between hospital admission and intervention, treatment duration,&#xD;
      need of other strategies to stop pelvic bleeding, complications and mortality.&#xD;
&#xD;
      The objective of this study is to determinate if angioembolization is superior to&#xD;
      preperitoneal pelvic packing for pelvic bleeding control in unstable trauma patients due to&#xD;
      pelvic bleeding.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pelvic bleeding control based on clinical response</measure>
    <time_frame>24 hours</time_frame>
    <description>Clinical response after the intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional techniques</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Need for additional techniques after the intervention to control bleeding associated with pelvic fracture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-procedure complications</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Presence of post-procedure complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-procedure complications degree</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Description of post-procedure complications: Clavien Dindo scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-procedure complications degree</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Description of post-procedure complications: Comprehensive Complication Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Death of the pacient (cause and date)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood cell transfusion</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Need for blood cell transfusion for patients (number and need for masive transfusion protocol activation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until intervention</measure>
    <time_frame>Time until intervention (up to 60 minutes)</time_frame>
    <description>Time elapsed between hospital admission and intervention</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time until arrival at hospital</measure>
    <time_frame>Time until arrival at hospital (up to 30 minutes)</time_frame>
    <description>Time elapsed between prehospital attention and hospital admission</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of angioembolization</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Duration of angioembolization</description>
  </other_outcome>
  <other_outcome>
    <measure>Angioembolization treatment</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Arteries treated with angioembolization</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of Preperitoneal Pelvic Packing</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Duration of Preperitoneal Pelvic Packing</description>
  </other_outcome>
  <other_outcome>
    <measure>Intensive care unit stay</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Number of days that the patient remains in the intensive care unit</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital stay</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Number of days that the patient remains in hospital</description>
  </other_outcome>
  <other_outcome>
    <measure>Readmission</measure>
    <time_frame>30 days after discharge</time_frame>
    <description>Readmission 30 days after discharge</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Trauma</condition>
  <condition>Pelvic Fracture</condition>
  <condition>Hemodynamic Instability</condition>
  <arm_group>
    <arm_group_label>Angioembolization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Preperitoneal Pelvic Packing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Angioembolization</intervention_name>
    <description>Via the femoral route, a non-selective pelvic arteriography with a selective embolization of the arterial branches that show direct or indirect signs of injury will be performed.&#xD;
In the event of persistent hemodynamic instability after selective embolization, non-selective bilateral embolization of the internal iliac arteries will be evaluated.&#xD;
The material used will vary depending on the characteristics of the injury and the availability of the materials.</description>
    <arm_group_label>Angioembolization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Preperitoneal Pelvic Packing</intervention_name>
    <description>Pfannestiel incision / infraumbilical laparotomy. Dissection of tissues up to and including the transversalis fascia. Inferior to this and anterior to the peritoneum, the preperitoneal cavity is identified.&#xD;
Inclusion of radiopaque laparotomy gauze in each hemipelvis, from the posterior part (anterior to the sacro-iliac joint) to the most anterior in the retropubic position. Subsequently, the closure is carried out to increase the plugging effect.&#xD;
A second intervention is required to remove the material in 24-48 hours.</description>
    <arm_group_label>Preperitoneal Pelvic Packing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Systolic blood pressure ≤ 90 mmHg&#xD;
&#xD;
          -  Heart rate &gt; 100 bpm&#xD;
&#xD;
          -  Shock Index ≥ 0,8&#xD;
&#xD;
          -  Pelvic fracture&#xD;
&#xD;
          -  Negative FAST / peritoneal aspiration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other causes of bleeding that require treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nuria Llorach-Perucho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corporacion Parc Tauli</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salvador Navarro-Soto, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Corporacion Parc Tauli</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Campos-Serra, MD</last_name>
    <role>Study Director</role>
    <affiliation>Corporacion Parc Tauli</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nuria Llorach-Perucho, MD</last_name>
    <phone>0034656336708</phone>
    <email>nuriallorachperucho@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Salvador Navarro-Soto, MD, PhD</last_name>
    <email>snavarro@tauli.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Corporació Sanitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Nuria Llorach-Perucho, MD</last_name>
      <phone>0034656336708</phone>
      <email>nuriallorachperucho@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Nuria Llorach-Perucho</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Trauma</keyword>
  <keyword>Pelvis Fracture</keyword>
  <keyword>Hypovolemic Shock</keyword>
  <keyword>Preperitoneal Pelvic Packing</keyword>
  <keyword>Angioembolization</keyword>
  <keyword>Hemodynamic Instability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

